BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. Br J Anaesth 2019;122:e146-56. [PMID: 30916003 DOI: 10.1016/j.bja.2018.10.065] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Ding H, Kiguchi N, Mabry KM, Kishioka S, Ko M. Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109328] [Reference Citation Analysis]
2 Gerak LR, Maguire DR, Cami-Kobeci G, Olson KM, Traynor JR, Husbands SM, France CP, Acevedo L, Belli B, Flynn P. OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects. Behav Pharmacol 2022;33:377-94. [PMID: 35947066 DOI: 10.1097/FBP.0000000000000684] [Reference Citation Analysis]
3 Kong L, Shu X, Tang S, Ye R, Sun H, Jiang S, Li Z, Chai J, Fang Y, Lan Y, Yu L, Xie Q, Fu W, Wang Y, Li W, Qiu Z, Liu J, Shao L. SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity. J Med Chem 2022. [PMID: 35900351 DOI: 10.1021/acs.jmedchem.2c00014] [Reference Citation Analysis]
4 Coluzzi F, Rullo L, Scerpa MS, Losapio LM, Rocco M, Billeci D, Candeletti S, Romualdi P. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. CNS Drugs 2022. [PMID: 35616826 DOI: 10.1007/s40263-022-00924-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Dasgupta P, Mann A, Polgar WE, Reinscheid RK, Zaveri NT, Schulz S. Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics. Sci Rep 2022;12:7154. [PMID: 35504962 DOI: 10.1038/s41598-022-11189-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cippitelli A, Martinez M, Zribi G, Cami-kobeci G, Husbands SM, Toll L. PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cox BM, Toll L. Contributions of the International Narcotics Research Conference to Opioid Research Over the Past 50 years. Adv Drug Alcohol Res 2022;2. [DOI: 10.3389/adar.2022.10115] [Reference Citation Analysis]
8 Kiguchi N, Ding H, Park SH, Mabry KM, Kishioka S, Shiozawa Y, Alfonso Romero-Sandoval E, Peters CM, Ko MC. Functional roles of neuromedin B and gastrin-releasing peptide in regulating itch and pain in the spinal cord of non-human primates. Biochem Pharmacol 2022;198:114972. [PMID: 35189108 DOI: 10.1016/j.bcp.2022.114972] [Reference Citation Analysis]
9 El Daibani A, Che T. Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain. Molecules 2022;27:595. [PMID: 35163856 DOI: 10.3390/molecules27030595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Kiguchi N, Ko M. Potential therapeutic targets for the treatment of opioid abuse and pain. Behavioral Pharmacology of Drug Abuse: Current Status 2022. [DOI: 10.1016/bs.apha.2021.09.002] [Reference Citation Analysis]
11 Acevedo-canabal A, Pantouli F, Ravichandran A, Rullo L, Bohn LM. Pharmacological Diversity in Opioid Analgesics: Lessons From Clinically Useful Drugs. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00188-2] [Reference Citation Analysis]
12 Hedrick SL, Luo D, Kaska S, Niloy KK, Jackson K, Sarma R, Horn J, Baynard C, Leggas M, Butelman ER, Kreek MJ, Prisinzano TE. Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent. J Biomed Sci 2021;28:62. [PMID: 34503531 DOI: 10.1186/s12929-021-00758-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang W, Kong M, Dou Y, Xue S, Liu Y, Zhang Y, Chen W, Li Y, Dai X, Meng J, Wang J. Selective Expression of a SNARE-Cleaving Protease in Peripheral Sensory Neurons Attenuates Pain-Related Gene Transcription and Neuropeptide Release. Int J Mol Sci 2021;22:8826. [PMID: 34445536 DOI: 10.3390/ijms22168826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
14 Kiguchi N, Ding H, Kishioka S, Ko MC. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics. Curr Top Med Chem 2020;20:2878-88. [PMID: 32384033 DOI: 10.2174/1568026620666200508082615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
15 Ding H, Trapella C, Kiguchi N, Hsu FC, Caló G, Ko MC. Functional Profile of Systemic and Intrathecal Cebranopadol in Nonhuman Primates. Anesthesiology 2021. [PMID: 34237134 DOI: 10.1097/ALN.0000000000003848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Toll L, Cippitelli A, Ozawa A. The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies. CNS Drugs 2021;35:591-607. [PMID: 34057709 DOI: 10.1007/s40263-021-00821-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Pacifico S, Albanese V, Illuminati D, Marzola E, Fabbri M, Ferrari F, Holanda VAD, Sturaro C, Malfacini D, Ruzza C, Trapella C, Preti D, Lo Cascio E, Arcovito A, Della Longa S, Marangoni M, Fattori D, Nassini R, Calò G, Guerrini R. Novel Mixed NOP/Opioid Receptor Peptide Agonists. J Med Chem 2021;64:6656-69. [PMID: 33998786 DOI: 10.1021/acs.jmedchem.0c02062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Meyer ME, Doshi A, Yasuda D, Zaveri NT. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists. AAPS J 2021;23:68. [PMID: 33974173 DOI: 10.1208/s12248-021-00589-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bodnar RJ. Endogenous opiates and behavior: 2019. Peptides 2021;141:170547. [PMID: 33831447 DOI: 10.1016/j.peptides.2021.170547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
20 Ding H, Ko MC. Translational value of non-human primates in opioid research. Exp Neurol 2021;338:113602. [PMID: 33453211 DOI: 10.1016/j.expneurol.2021.113602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
21 Ko MC, Husbands SM. Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates. Handb Exp Pharmacol 2020. [PMID: 33274403 DOI: 10.1007/164_2020_419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Zhang M, Xu B, Li N, Liu H, Shi X, Zhang Q, Shi Y, Xu K, Xiao J, Chen D, Zhu H, Sun Y, Zhang T, Zhang R, Fang Q. Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception. J Med Chem 2020;63:15709-25. [PMID: 33271020 DOI: 10.1021/acs.jmedchem.0c01367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Gibula-Tarlowska E, Kotlinska JH. Crosstalk between Opioid and Anti-Opioid Systems: An Overview and Its Possible Therapeutic Significance. Biomolecules 2020;10:E1376. [PMID: 32998249 DOI: 10.3390/biom10101376] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
24 Ding H, Kiguchi N, Perrey DA, Nguyen T, Czoty PW, Hsu FC, Zhang Y, Ko MC. Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates. Br J Anaesth 2020;125:596-604. [PMID: 32819621 DOI: 10.1016/j.bja.2020.06.057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
25 Kiguchi N, Ding H, Ko MC. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. J Neurosci Res 2020. [PMID: 32255240 DOI: 10.1002/jnr.24624] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
26 King A. Analgesia without opioids. Nature 2019;573:S4-6. [DOI: 10.1038/d41586-019-02683-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Kiguchi N, Ko MC. Effects of NOP-Related Ligands in Nonhuman Primates. Handb Exp Pharmacol 2019;254:323-43. [PMID: 30879202 DOI: 10.1007/164_2019_211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
28 Hemmings HC, Lambert DG. The good, the bad, and the ugly: the many faces of opioids. British Journal of Anaesthesia 2019;122:705-7. [DOI: 10.1016/j.bja.2019.04.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 Lambert DG. Mixed mu-nociceptin/orphanin FQ opioid receptor agonists and the search for the analgesic holy grail. British Journal of Anaesthesia 2019;122:e95-7. [DOI: 10.1016/j.bja.2019.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]